@entity2449 use and the risk of XXXX in @entity355 .

@entity1 @entity6 @entity355 @entity5 @entity1780 @entity418 @entity420 @entity2449
OBJECTIVES: @entity6 is a significant risk factor for total @entity5 incidence and mortality. @entity2449 , a commonly used antidiabetic drug, has been shown to be protective against different types of @entity5 ; however, its role in @entity418 is unknown. The goal of this study was to determine whether the use of @entity2449 modifies the risk of development of @entity420 in @entity1 with @entity355 . METHODS: @entity1 with diagnoses of @entity355 and @entity418 were identified during a 20-year period. Demographic and clinical data were collected. The outcome variable was @entity420 . Univariate analysis was performed using two-sample t tests for continuous variables or the Fisher exact test for categorical variables. Multiple logistic regression analysis was then performed using the significant variables. RESULTS: A total of 583 @entity1 were identified with the diagnosis of @entity355 or @entity420 from 1992 to 2012. Of these, 115 had @entity420 and 468 had @entity355 . Age, smoking, and @entity6 were found to be significant risk factors for the development of @entity418 with the following results: age (P < 0.001), smoking (P = 0.003), @entity6 (P = 0.007). @entity1780 use was protective against the development of @entity5 with P = 0.001. @entity2449 use was neither associated with an increased nor a decreased risk of @entity418 . CONCLUSIONS: The three independent variables that predicted progression of @entity355 to @entity420 in our study were older age, smoking, and @entity6 . Statin use showed protective effect against development of @entity420 . @entity2449 use did not demonstrate any statistically significant protective effect.
